Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Klein on Oncotype DX in Predicting Outcomes in African Americans With Prostate Cancer

May 20th 2020

Eric A. Klein, MD, discusses the utility of Oncotype DX Genomic Prostate Score in predicting outcomes in African American men with prostate cancer.

Agarwal Outlines Importance of Olaparib Approval in HRR-Mutant mCRPC

May 20th 2020

Neeraj Agarwal, MD, provides insight into olaparib, further discusses the data that led to the regulatory approval, and shares the implications of this approval in metastatic castration-resistant prostate cancer.

Agarwal Outlines Importance of Olaparib Approval in HRR-Mutant mCRPC

May 20th 2020

Neeraj Agarwal, MD, provides insight into olaparib, further discussed the data that led to the regulatory approval, and shared the implications of this approval in metastatic castration-resistant prostate cancer.

Dr. Bryce on the FDA Approval of Rucaparib in BRCA-Mutant mCRPC

May 20th 2020

Alan H. Bryce, MD, discusses the accelerated approval of rucaparib (Rubraca) for the treatment of adult patients with BRCA mutation (germline and/or somatic)–associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor–directed therapy and a taxane-based chemotherapy.

Dr. Klein on the Importance of the Importance of Prognostic Genomic Assays in Prostate Cancer

May 20th 2020

Eric A. Klein, MD, discusses the importance of providing genomic testing to patients with prostate cancer.

Dr. Jain on the Use of Diagnostic Tracers in Prostate Cancer

May 19th 2020

Manoj K. Jain, MD, discusses diagnostic tracers in prostate cancer.

Dr. Kohli on the Use of Enzalutamide and Apalutamide in mHSPC

May 19th 2020

Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Vogelzang: Rucaparib Approval Raises New Hope in mCRPC

May 16th 2020

Nicholas J. Vogelzang, MD, discusses the significance of the rucaparib approval for this patient population.

Dr. Koo on the Need for Next-Generation Imaging in Prostate Cancer

May 16th 2020

Phillip J. Koo, MD, discusses the need for next-generation imaging in prostate cancer.

Dr. Vargas on Research With Proton Therapy in Prostate Cancer

May 16th 2020

Carlos E. Vargas, MD, discusses research with proton therapy in prostate cancer.

FDA Approves Rucaparib for BRCA+ mCRPC

May 15th 2020

The FDA has approved rucaparib for the treatment of adult patients with BRCA-mutant recurrent, metastatic castration-resistant prostate cancer.

Dr. Penson on Ongoing Research in Prostate Cancer

May 15th 2020

David F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.

Dr. Dahut on the Future of Genetic Screening in Prostate Cancer

May 15th 2020

William L. Dahut, MD, discusses the future of genetic screening in prostate cancer.

Challenges of Implementing Alternative Delivery Models for Genetic Counseling in Prostate Cancer

May 14th 2020

Alanna K. Rahm, PhD, MS, discusses the challenges of implementing alternate delivery models for genetic counseling in prostate cancer.

Dr. Heath on Developments in Nonmetastatic CRPC

May 13th 2020

Elisabeth I. Heath, MD, FACP, discusses developments in nonmetastatic castration-resistant prostate cancer (CRPC).

Dr. Freedland on Real-World Utility of Enzalutamide in Prostate Cancer

May 12th 2020

Stephen J. Freedland, MD, discusses remaining questions with the real-world utility of enzalutamide in prostate cancer.

Sawyers Explains Lessons Learned After Atezolizumab/Enzalutamide Falls Short in mCRPC

May 8th 2020

Charles L. Sawyers, MD, discusses the implications of the IMbassador250 trial, other notable presentations delivered at the meeting, and exciting research efforts being made in prostate cancer and beyond.

Dr. Higano on the State of Immunotherapy in Prostate Cancer

May 8th 2020

Celestia S. Higano, MD, FACP, discusses the state of immunotherapy in prostate cancer.

Dr. Shinohara on Pairing SBRT With Immunotherapy in Prostate Cancer

May 8th 2020

Eric Shinohara, MD, MSCI, discusses the potential to combine stereotactic body radiotherapy with immunotherapy in prostate cancer.

DNA-PK as an Emerging Target in Prostate Cancer

May 7th 2020

Karen E. Knudsen, PhD, chair and Hilary Koprowski Professor, Department of Cancer Biology, professor of cancer biology, urology, medical oncology, and radiation oncology, and enterprise director, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, discusses DNA-dependent protein kinase (DNA-PK) as an emerging target in prostate cancer.